To address the need for rapid, accessible HCV RNA testing at the point of care, specifically targeting barriers such as cost, complexity, and access to laboratory-based testing to facilitate diagnosis and treatment.
Key Findings:
DASH® HCV assay achieved 15-minute results, improving potential for same-day treatment and enhancing patient engagement.
Demonstrated high analytical specificity and dynamic range of 256–4,000,000 IU/mL, indicating robustness across various viral loads.
Successful extraction of nucleic acid from whole blood using optimized solid-phase extraction, which is crucial for point-of-care settings.
Interpretation:
The DASH® Rapid PCR Platform represents a significant advancement in HCV testing, potentially overcoming barriers to diagnosis and treatment by providing rapid results, which can lead to timely interventions and improved patient outcomes.
Limitations:
Further validation with larger numbers of contrived whole blood specimens, including diverse demographics, is needed.
Real-world performance evaluation using fresh capillary blood is critical to assess practical applicability.
Conclusion:
The development of a rapid point-of-care HCV RNA test could enhance testing uptake and treatment opportunities, significantly contributing to global HCV elimination efforts.
